# PD-1 Blockade Combined With Chemotherapy Followed by Concurrent Immunoradiotherapy for Locally Advanced SCCA Patients

> **NCT05060471** · PHASE2 · COMPLETED · sponsor: **Sun Yat-sen University** · enrollment: 25 (actual)

## Conditions studied

- Anal Canal Cancer
- Anal Squamous Cell Carcinoma
- Anal Cancer
- Anal Canal Cancer Stage I
- Anal Canal Cancer Stage II
- Anal Canal Cancer Stage III

## Interventions

- **DRUG:** Toripalimab

## Key facts

- **NCT ID:** NCT05060471
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-10-27
- **Primary completion:** 2024-06-21
- **Final completion:** 2024-11-27
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2024-12-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05060471

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05060471, "PD-1 Blockade Combined With Chemotherapy Followed by Concurrent Immunoradiotherapy for Locally Advanced SCCA Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05060471. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*